These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 9421870)
21. A modification of Simon's optimal design for phase II trials when the criterion is median sample size. Hanfelt JJ; Slack RS; Gehan EA Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296 [TBL] [Abstract][Full Text] [Related]
22. Optimal designs for phase II clinical trials with heterogeneous patient populations. Liu L; Cao S; Jung SH J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review. Yoo W; Kim S; Garcia M; Mehta S; Sanai N BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391 [TBL] [Abstract][Full Text] [Related]
24. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints. Kunz CU; Kieser M Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719 [TBL] [Abstract][Full Text] [Related]
25. Extended two-stage adaptive designs with three target responses for phase II clinical trials. Kim S; Wong WK Stat Methods Med Res; 2018 Dec; 27(12):3628-3642. PubMed ID: 28535716 [TBL] [Abstract][Full Text] [Related]
26. [Research design for patient selection in clinical trials phase II]. Kramar A; Potvin D; Hill C Rev Epidemiol Sante Publique; 1996 Aug; 44(4):364-71. PubMed ID: 8927779 [TBL] [Abstract][Full Text] [Related]
27. Two-stage k-sample designs for the ordered alternative problem. Shan G; Hutson AD; Wilding GE Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050 [TBL] [Abstract][Full Text] [Related]
28. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution. Liu J; Lin Y; Shih WJ Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506 [TBL] [Abstract][Full Text] [Related]
29. Two-stage optimal designs with survival endpoint when the follow-up time is restricted. Shan G; Zhang H BMC Med Res Methodol; 2019 Apr; 19(1):74. PubMed ID: 30943896 [TBL] [Abstract][Full Text] [Related]
30. Curtailed two-stage designs in Phase II clinical trials. Chi Y; Chen CM Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510 [TBL] [Abstract][Full Text] [Related]
31. Optimal multi-stage designs for a phase II trial that permits one dose escalation. Hanfelt JJ Stat Med; 1999 Jun; 18(11):1323-39. PubMed ID: 10399199 [TBL] [Abstract][Full Text] [Related]
32. Proper inference from Simon's two-stage designs. Koyama T; Chen H Stat Med; 2008 Jul; 27(16):3145-54. PubMed ID: 17960777 [TBL] [Abstract][Full Text] [Related]
33. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design. Wu Y; Shih WJ Stat Med; 2008 Dec; 27(29):6190-208. PubMed ID: 18800338 [TBL] [Abstract][Full Text] [Related]
34. Approximately optimal designs for phase II clinical studies. Stallard N J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860 [TBL] [Abstract][Full Text] [Related]
35. Phase II cancer clinical trials with heterogeneous patient populations. Jung SH; Chang MN; Kang SJ J Biopharm Stat; 2012; 22(2):312-28. PubMed ID: 22251176 [TBL] [Abstract][Full Text] [Related]
36. Randomized phase II trials with a prospective control. Jung SH Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688 [TBL] [Abstract][Full Text] [Related]
37. Boundary problem in Simon's two-stage clinical trial designs. Shan G; Chen JJ; Ma C J Biopharm Stat; 2017; 27(1):25-33. PubMed ID: 26881325 [TBL] [Abstract][Full Text] [Related]
38. Randomized phase II designs in cancer clinical trials: current status and future directions. Lee JJ; Feng L J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154 [TBL] [Abstract][Full Text] [Related]
39. Optimal two-stage designs for single arm phase II cancer trials. Shuster J J Biopharm Stat; 2002 Feb; 12(1):39-51. PubMed ID: 12146719 [TBL] [Abstract][Full Text] [Related]
40. Adaptive designs for single-arm phase II trials in oncology. Englert S; Kieser M Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]